HHS asks whether to rename or add vaccine recommendation categories; comments due Sept. 20

Two weeks ago the White House sorted every childhood vaccine into three federal categories [2]. On August 24, HHS published a request asking whether those three categories are the right ones at all, and whether a vaccine moved between them would keep the coverage it has today [1].

What changed

The notice, a request for information (RFI) signed by HHS Secretary Robert F. Kennedy Jr., appeared in the Federal Register at 91 FR 54724 under Docket No. HHS-OS-2026-0332 [1]. HHS announced it August 21 [3]. Comments must be received by September 20, 2026, through regulations.gov or by mail [1].

It asks whether the three categories now used in federal immunization schedules are “adequate, clear, and well understood by clinicians, patients, and parents” [1]. Those categories are routine (universal) recommendations, risk-based recommendations, and recommendations based on shared clinical decision-making (SCDM), which HHS and the Advisory Committee on Immunization Practices (ACIP) have also called individual-based decision-making since 2025 [1]. The RFI floats new or different labels, including “recommended, but not during infancy,” “recommended with qualification” and “shared clinical decision-making with qualification” [1].

HHS says the notice “does not constitute a rule, a proposed rule, or a recommendation, and it does not alter any existing vaccine recommendation, coverage requirement, or program obligation” [1].

Who it affects

Any practice that gives vaccines works inside these categories, but the RFI’s questions land hardest in three places.

• Pediatric and family medicine practices. The request is issued in support of Executive Order 14420, signed August 10 and published August 14, which lists childhood immunizations in three groups [1, 2]. Measles, mumps, rubella, diphtheria, tetanus, pertussis, polio, Hib, pneumococcal disease, HPV and varicella are recommended for all children; RSV monoclonal antibodies, hepatitis A, hepatitis B, meningococcal B, meningococcal ACWY and dengue for high-risk groups; and hepatitis A, hepatitis B, rotavirus, meningococcal disease, influenza and COVID-19 under shared clinical decision-making [2].
• Vaccines for Children (VFC) providers. The RFI asks what would be needed to keep “predictable and consistent treatment under coverage requirements, program eligibility rules, the injury-compensation programs, and State law” if new categories were adopted [1].
• Adult and internal medicine practices. The categories apply to the adult schedule too, and the physician survey HHS cites on SCDM workload was about adult immunization [1].

Are shared clinical decision-making vaccines still covered?

Yes, under the rules in force on the day of publication. HHS states it directly: an SCDM recommendation, once adopted by the CDC director, “triggers the same coverage requirements as a routine recommendation, including coverage without cost-sharing under the Affordable Care Act and availability through the Vaccines for Children program” [1].

The notice also concedes that many clinicians do not know this. In a 2018 national survey HHS cites, only 24% of pediatric primary care providers could define the old permissive “Category B” recommendation, and a majority did not know such vaccines were covered by private insurance or VFC [1]. In a 2021 physician survey on adult SCDM recommendations, fewer than half knew SCDM vaccines were covered, and about 90 to 95% said SCDM recommendations take more time to carry out than routine ones [1]. Many in that survey reported that electronic health records and immunization forecasting tools showed SCDM recommendations inaccurately or not at all [1].

That is why question 12 of the RFI asks how HHS should teach the public and “the provider community” that SCDM vaccines are covered, so the designation is “not misread as a lapse in coverage or a signal that a vaccine is unavailable” [1]. Question 6 asks the harder question: if a new category were created, how coverage and program eligibility would attach to it [1]. The notice does not answer that.

What it means for your practice

Nothing in your vaccine billing, VFC ordering or patient cost sharing changes because of this notice [1]. What it signals is the direction of the work that follows.

Your schedule display may be the weak point. If the executive order’s lists move more childhood vaccines into the SCDM column, the evidence HHS itself cites says the visible risk is confusion, not loss of coverage [1, 2]. A forecasting tool that hides or mislabels SCDM vaccines can make a covered shot look optional or unpaid at the front desk [1].

Documentation may get its own standard. The RFI asks what supports would make SCDM work, naming “decision aids, provider training, documentation standards, coverage clarifications” and category-specific materials [1]. A documentation standard, if HHS adopts one, would land on the clinician who has the conversation.

Visit patterns could change. The executive order says that “to the maximum extent feasible, all childhood immunizations should be administered at separate medical visits,” and that combined MMR should be given as three single-disease shots once those products are domestically available [2]. The RFI asks separately about guidance on giving vaccines individually versus at a single visit [1]. Patient Care Online noted that the order does not set future coverage or cost-sharing rules and does not explain how separate visits would work in practice [4]. BioSpace reported that drugmakers have said splitting MMR would take years [5].

Timing flexibility is on the table. HHS asks whether clearer age windows, such as the 12-through-15-month window for the first measles-containing dose, would help families see that a vaccine is recommended while allowing flexibility in when it is given [1].

What to do now

1. Decide whether to comment. If a new category or renamed SCDM label would change your workflow, say how in Docket HHS-OS-2026-0332 by September 20 [1]. HHS asks commenters for data and concrete examples and says commenters need not answer every question [1].
2. Audit your forecasting tools. Check how your EHR displays the vaccines the order lists under shared clinical decision-making, especially hepatitis B, rotavirus, influenza and COVID-19 [1, 2].
3. Brief front-desk and billing staff. Make sure they know SCDM vaccines are covered without cost sharing and through VFC under current rules [1].
4. Watch for the task force plans. The order gives the HHS Task Force on Safer Childhood Vaccines 90 days to present plans on single-antigen options, timing and sequencing of the schedule, and safety monitoring [2]. Patient Care Online put that deadline at November 8, 2026 [4].

The policy fight

HHS frames the request around trust. The notice argues that recommendations “perceived as premature, overconfident, or insulated from candor about uncertainty” carry lasting costs for all federal vaccine recommendations, “including those resting on the strongest evidence” [1]. It says “Federal recommendations are recommendations, not mandates,” and that the distinction “should be preserved and made legible to the public” [1]. It also asks whether the SCDM label wrongly suggests that consent and parental permission matter only for that category [1, 5].

The White House order says an HHS assessment found the United States recommends more childhood vaccines than any peer nation, and that earlier directives were delayed by “litigation over the composition of the Advisory Committee on Immunization Practices” [2]. It sets a policy that federal programs “should support maximal parental choice over childhood vaccines” [2].

Physician groups opposed the order when it was signed. American Academy of Pediatrics President Andrew Racine said, “Delaying or skipping shots is risky, especially as measles continues to spread and children go back to school,” according to Patient Care Online [4]. American Medical Association President Willie Underwood III said, “Altering a proven vaccination schedule without credible evidence risks weakening public confidence and putting children’s health at risk” [4]. Robert H. Hopkins Jr., medical director of the National Foundation for Infectious Diseases, said, “Changes made without that evidence risk weakening the protections children have today” [4]. BioSpace reported that health care providers have pushed back on the order [5].

The notice itself records the split. It cites research finding that mandates provoke reactance and distrust, then says “the empirical literature is mixed,” pointing to studies in which requirements raised uptake [1]. It cites evidence that uptake of SCDM vaccines has been lower than for routine ones, and also surveys in which physicians supported keeping an SCDM category for some vaccines [1]. Which of those findings HHS weighs most will show up only in what the task force proposes.